Getting Biased Treatment Study: How Psychotherapy and Antidepressants Change Brain Activity in Chronic Depression
NCT ID: NCT00596986
Last Updated: 2009-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2008-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Maintaining Mechanisms of Chronic Depression and Their Changeability
NCT02801513
Functional and Metabolic Changes in the Course of Antidepressive Treatment
NCT02099630
Stress Systems and Psychotherapy in Depression
NCT03752853
Using Affective Differences to Predict Response to Behavioral Treatment for Major Depressive Disorder
NCT00909220
Evaluation of Use of Brain Activity Monitoring for Evaluation of Depression Treatment
NCT02523105
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AD
Antidepressant Duloxetine
Duloxetine
Duloxetine 30mg up to 120mg per day.
PT
Psychotherapy (CBASP) - Cognitive Behavioural Analysis System of Psychotherapy
Cognitive Behavioural Analysis System of Psychotherapy
Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Duloxetine
Duloxetine 30mg up to 120mg per day.
Cognitive Behavioural Analysis System of Psychotherapy
Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* HAMD-24\>20
Exclusion Criteria
* Previous Non-Response to Duloxetine
* Non-Response to three Antidepressants of two different groups given at adequate doses or Non-Response to two empirically tested forms of Psychotherapy in the current Depressive Episode
* Serious Psychiatric comorbidity
* Serious Neurologic comorbidity
* Contraindications to Duloxetine
* Contraindications to fMRI
18 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Federal Ministry of Education and Research
OTHER_GOV
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dept. of Psychiatry, Campus Benjamin Franklin, Charite University, Berlin, Germany
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isabella Heuser, Prof. Dr. med. Dipl. Psych.
Role: STUDY_CHAIR
Dept. of Psychiatry, Campus Benjamin Franklin, Charité Berlin, Germany
Michael Colla, Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Department of Psychiatry, Campus Benjamin Franklin, Charité Berlin, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charité Universitätsmedizin
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUK-B2
Identifier Type: -
Identifier Source: secondary_id
EUK-B2.1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.